fashion -WSS

fashion

author：fashion 2025-10-01 18:32:36 - browse：27

KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a Phase 3 clinical trial.

Based on the study results, the company plans to submit a marketing application to the Food and Drug Administration by the middle of the year. Regulatory filings in Europe and Japan will be completed later in the year.

In the Phase 3 study involving 136 participants, a low and high dose of Kalvista’s drug, called sebetralstat, showed a median time to the beginning of symptom relief of 1.6 hours and 1.8 hours, respectively, compared to 6.7 hours for a placebo. The result was statistically significant and achieved the study’s main efficacy goal.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： A single drug, study failures leave Anavex with nothing but cash

WSS

AdventHealth escalates lawsuit against insurance vendor Multiplan

FDA panel gives mixed vote on blood pressure devices

FDA panel gives mixed vote on blood pressure devices

Videos point to link between seizures and unexplained toddler deaths

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

hotspot

fashion

Wikipedia

Malaria cases in Florida and Texas: Here’s what you need to know

3 medical device trends to watch in 2024

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Why more medical students aren't specializing in primary care

Medicare proposal to cover medical devices draws a mixed reaction

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

How one medical school became remarkably diverse

U.K. sequencing study surfaces new findings about tumor DNA

Medical leaders decry Supreme Court decision on affirmative action

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

focus

How to make AI work for medicine

Diversity in medical illustrations gets boost from Chidiebere Ibe

Goldman Sachs launches $650M fund for life science investments

How a scoliosis diagnosis changed the life of one young dancer

What AAP's gender

Why more medical students aren't specializing in primary care

leisure time

knowledge

leisure time

hotspot